

*Live-Cell Microfluidic Platform – Unlocking Novel Biomarkers, Cell-Based Assays and Diagnostics*

## Cellanyx Diagnostics News – Announcement of New Board Member Mr. Peter Parker

February 15, 2013

Cellanyx is pleased to announce the appointment of Mr. Peter Parker to its Senior Advisory Board. Senior Advisory Board (SAB) members play a vital role in a company as they help better understand the market, assess financial conditions that will continue to strengthen the company, and advise on clinical, strategic, and technical developments. Importantly, Cellanyx's SAB members share business, scientific, process and regulatory practices that keep the company operating according to the highest standards.

Mr. Parker comes with tremendous business and leadership talent. Currently, Mr. Parker is Founder and Director of LabCentral, Inc, a non-profit laboratory space for startup biotech companies. For nearly 20 years, Mr. Parker was a General Partner at Ampersand Capital Partners, Wellesley MA, where he focused on the firm's Life Sciences activities. From 2006–2010 he was President and CEO of Cequent Pharmaceuticals (sold to Marina Biotech (NSDQ: MRNA) July, 2010). He has served as a director of numerous companies including ACLARA Biosciences, Tomah Products, VITEX, Magellan Biosciences, Dynex, Castlewood Surgical and Pentose Pharmaceuticals and as Chairman of Alexis, NOVEX, CoPharma, Huntington Laboratories, Protein Ingredient Technologies, Cyclis Pharmaceuticals, Nanodyne, Panacos Pharmaceuticals, AC Tech, BioEssences and TekCel. Prior to Ampersand, Mr. Parker spent fourteen years at AMAX, Inc.

Mr. Parker is eager to gain a more in-depth understanding of the cancer diagnostics sector, tour Cellanyx's facilities and begin service to the Board. Cellanyx expects that he will bring strong insights and great value to the organization.

Cellanyx is combining advances in microfluidics, bioengineering, machine vision and cellomics to provide a state-of-the-art live-cell cancer diagnostic solution.

###

---

For more information, news, and perspectives from Cellanyx, please visit the website at <http://www.cellanyx.com>, or please contact:

Cellanyx Diagnostics, Inc.  
One Marina Park Drive,  
14th floor  
Boston, MA, 02210  
Main: 571.212.9991  
Email: [info@cellanyx.com](mailto:info@cellanyx.com)